Drug intelligence / Profile preview

furestem-cd

Development stage: Phase 2
Lead developer: Kangstem Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

FURESTEM-CD is an allogeneic stem cell therapy consisting of mesenchymal stem cells derived from human umbilical cord blood (UCB-MSCs). It is administered through intravenous injection and is primarily being developed for the treatment of moderate to severe Crohn's disease. The stem cells possess properties of self-proliferation, immunomodulation, and pluripotency, offering advantages over mesenchymal stem cells sourced from bone marrow or subcutaneous fat, including easier isolation and faster population doubling time.

Brand names: FURESTEM-CD Inj
Other names: hUCB-MSCs

Beyond the preview

Go deeper on furestem-cd.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on furestem-cd.

Explore the full profile